Skip to content
The POSEIDON Trial With Tejas Patil episode artwork

Nov 28, 2022 33 min

The POSEIDON Trial With Tejas Patil

from Lung Cancer Considered Hosted by IASLC

Dr. Narjust Florez discusses the POSEIDON trial with guest Dr. Tejas Patil, assistant professor at Thoracic Oncology Research Initiative, University of Colorado Cancer Center. This Phase III study led to the recent FDA approval of Tremelimumab in combination with Durvalumab and chemotherapy as first line treatment in patients with metastatic non small-cell lung cancer (NSCLC).

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

The POSEIDON Trial With Tejas Patil

0:00 33:16

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Lung Cancer Considered?

This episode is 33 minutes long.

When was this Lung Cancer Considered episode published?

This episode was published on November 28, 2022.

Can I download this Lung Cancer Considered episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.